Therefore, anti-tumor activity of nivolumab and ipilimumab, an anti-CTLA-4 antibody as combinatorial therapy is currently under evaluation in phase II clinical trial in patients with rare tumor types, including NPC (NCT02834013) (Table 3). This evidence concerns the gene CTLA4 and neoplasm.